Molecular diagnostic company Diatech Pharmacogenetics has partnered with Janssen Pharmaceutica NV to enhance access to precision medicine for bladder cancer patients.
Diatech is developing a molecular test for bladder cancer that will enable personalized drug treatments based on patients' genetic profiles. It aims to make precision oncology testing globally accessible using a highly sensitive and fast analysis procedure. The collaboration with Janssen will contribute to advancing precision testing in oncology, providing more value to cancer patients.
Diatech Pharmacogenetics is an Italian company that specializes in the development, manufacturing, and commercialization of molecular diagnostic tools for precision oncology medicine. The company focuses on genomics testing solutions that identify gene mutations and genetic variations targeted by cancer therapies.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.